FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362542287> ?p ?o ?g. }

• W4362542287 endingPage "938" @default.
• W4362542287 startingPage "938" @default.
• W4362542287 abstract "Abstract Introduction: Molecular Tumor Boards (MTB) are essential in Precision Oncology Programs. Gaps, however, remain in interpreting comprehensive genomic profiling (CGP) results, and determining their actionability. Our MTB, established in October 2020 and conducted at a tertiary cancer center in Saudi Arabia, focused on discussing patients with complex CGP results and recommending genomic based therapies. Meetings occurred virtually, every month, with oncologists, pathologists and genomicists attending. Methods: This is a retrospective cohort study of patients discussed in our MTB from October 2020 till October 2022. We report the outcomes of these patients who had progressive disease on standard of care (SOC) therapies, and have had non Tier 1 alterations (ESCAT classification) in their CGP reports. We chose an FDA approved, commercially available CGP, which tests 324 genes (FoundationOne CDX). We present the demographics, clinical characteristics, CGP results, recommendations of the MTB, and patient outcomes. Results: Sixty patients fitting the criteria above have been discussed. Median number of prior systemic therapy lines was 2 (range 0-8). The most common primary diagnosis was soft tissue sarcoma (25%), followed by liver and pancreato-biliary cancers (20%), followed by head and neck cancers (15%) and skin cancers (8%). Of the 60 patients, 48 patients had response evaluations. Thirty five patients (out of 48, 73%) have had recommendations for genomic based therapies based on their CGP results. Only 16 patients (out of 35, 46%) received MTB recommended therapies. Eight patients (out of 16, 50%) have remained progression free and on MTB recommended genomic therapy for 6 months and above. The commonest reasons for not receiving MTB recommended therapy were patient clinical deterioration or death (9 patients, 47%) followed by patients responding on current line of therapy (7 patients, 37%). Most common pathogenic targetable alterations were CDKN2A/B mutations (6 patients), followed by alterations in FGFR (5 patients), PTEN (4 patients), BRAF (4 patients), PIK3CA (2 patients) and ERBB2 (2 patients) followed by others (will be presented). Conclusion: Following recommendations, of the first MTB in Saudi Arabia, resulted in improved outcomes of cancer patients who had progressive disease on SOC therapies. Consideration of performing CGP and discussing patients early in their cancer journey may allow them to receive, and benefit from recommended genomic therapies earlier. Citation Format: Kanan Alshammari, Fouad Sabatin, Mehlika Hazar-Rethinam, Faizah Alotaibi, Reham Ajina, Hussam Shehata, Mohammad Alkhayyat, Abdullah Alsaleh, Mohammed Algarni. Outcomes of molecular tumor board recommendations for cancer patients with progression on standard of care therapies in Saudi Arabia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 938." @default.
• W4362542287 created "2023-04-06" @default.
• W4362542287 creator A5003203438 @default.
• W4362542287 creator A5026584399 @default.
• W4362542287 creator A5032871350 @default.
• W4362542287 creator A5033500581 @default.
• W4362542287 creator A5034216445 @default.
• W4362542287 creator A5051854920 @default.
• W4362542287 creator A5072525821 @default.
• W4362542287 creator A5083163695 @default.
• W4362542287 creator A5091320228 @default.
• W4362542287 date "2023-04-04" @default.
• W4362542287 modified "2023-09-30" @default.
• W4362542287 title "Abstract 938: Outcomes of molecular tumor board recommendations for cancer patients with progression on standard of care therapies in Saudi Arabia" @default.
• W4362542287 doi "https://doi.org/10.1158/1538-7445.am2023-938" @default.
• W4362542287 hasPublicationYear "2023" @default.
• W4362542287 type Work @default.
• W4362542287 citedByCount "0" @default.
• W4362542287 crossrefType "journal-article" @default.
• W4362542287 hasAuthorship W4362542287A5003203438 @default.
• W4362542287 hasAuthorship W4362542287A5026584399 @default.
• W4362542287 hasAuthorship W4362542287A5032871350 @default.
• W4362542287 hasAuthorship W4362542287A5033500581 @default.
• W4362542287 hasAuthorship W4362542287A5034216445 @default.
• W4362542287 hasAuthorship W4362542287A5051854920 @default.
• W4362542287 hasAuthorship W4362542287A5072525821 @default.
• W4362542287 hasAuthorship W4362542287A5083163695 @default.
• W4362542287 hasAuthorship W4362542287A5091320228 @default.
• W4362542287 hasConcept C121608353 @default.
• W4362542287 hasConcept C126322002 @default.
• W4362542287 hasConcept C141071460 @default.
• W4362542287 hasConcept C142724271 @default.
• W4362542287 hasConcept C143998085 @default.
• W4362542287 hasConcept C167135981 @default.
• W4362542287 hasConcept C2777106319 @default.
• W4362542287 hasConcept C2778256501 @default.
• W4362542287 hasConcept C71924100 @default.
• W4362542287 hasConcept C72563966 @default.
• W4362542287 hasConceptScore W4362542287C121608353 @default.
• W4362542287 hasConceptScore W4362542287C126322002 @default.
• W4362542287 hasConceptScore W4362542287C141071460 @default.
• W4362542287 hasConceptScore W4362542287C142724271 @default.
• W4362542287 hasConceptScore W4362542287C143998085 @default.
• W4362542287 hasConceptScore W4362542287C167135981 @default.
• W4362542287 hasConceptScore W4362542287C2777106319 @default.
• W4362542287 hasConceptScore W4362542287C2778256501 @default.
• W4362542287 hasConceptScore W4362542287C71924100 @default.
• W4362542287 hasConceptScore W4362542287C72563966 @default.
• W4362542287 hasIssue "7_Supplement" @default.
• W4362542287 hasLocation W43625422871 @default.
• W4362542287 hasOpenAccess W4362542287 @default.
• W4362542287 hasPrimaryLocation W43625422871 @default.
• W4362542287 hasRelatedWork W2015694191 @default.
• W4362542287 hasRelatedWork W2035682242 @default.
• W4362542287 hasRelatedWork W2071535500 @default.
• W4362542287 hasRelatedWork W2091020218 @default.
• W4362542287 hasRelatedWork W2315085516 @default.
• W4362542287 hasRelatedWork W2603773853 @default.
• W4362542287 hasRelatedWork W3013145321 @default.
• W4362542287 hasRelatedWork W3210359220 @default.
• W4362542287 hasRelatedWork W4226062074 @default.
• W4362542287 hasRelatedWork W4313574608 @default.
• W4362542287 hasVolume "83" @default.
• W4362542287 isParatext "false" @default.
• W4362542287 isRetracted "false" @default.
• W4362542287 workType "article" @default.